![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 19, 2020
September 14, 2020
This is the only study that is currently designed to test the ability to improve long-term outcomes by refining early-setting triple-negative breast cancer chemotherapy without exposing ALL patients to more toxicity preoperatively
July 29, 2020
In the fifth month of restrictions due to COVID-19, member institutions pivot back to focus on general health care; clinical trial enrollments begin to rise back up to pre-pandemic levels; Fall 2020 Group Meeting to be virtual; EA holds first meeting of planned move to an anti-racist agenda
July 29, 2020
In July, the field of radiology lost one its most influential leaders
July 29, 2020
Currently, there is no treatment standard for metastatic pancreatic cancer in people aged 65 years and older
July 29, 2020
A special webcast in June focused on moving to an explicit anti-racist ECOG-ACRIN agenda
July 29, 2020
A Standing Main Member of ECOG-ACRIN since 1996
July 29, 2020
June 10, 2020
Strong EA research presence at ASCO 2020; the horrific killing of George Floyd; health equity and diversity in the field of oncology; the need for EA to participate in changing a specifically anti-racist culture and increase diversity and inclusion
June 10, 2020
This phase III trial is testing the antibody durvalumab added to standard chemoradiation followed by durvalumab for one year, compared to standard chemoradiation followed by one year of the antibody
June 10, 2020
This phase II study is exploring the potent FLT3 inhibitor gilteritinib
June 10, 2020
The study results, as well as correlative analyses, will be reported in an upcoming medical meeting